Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Vitamin B9  COVID-19 treatment studies for Vitamin B9  C19 studies: Vitamin B9  Vitamin B9   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -164% Improvement Relative Risk Case -51% Topless et al. Vitamin B9 for COVID-19 Prophylaxis Is prophylaxis with vitamin B9 beneficial for COVID-19? Retrospective 376,254 patients in the United Kingdom Higher mortality (p<0.0001) and more cases (p<0.0001) Topless et al., BMJ Open, doi:10.1136/bmjopen-2022-062945 Favors vitamin B9 Favors control
Folic acid and methotrexate use and their association with COVID-19 diagnosis and mortality: a case–control analysis from the UK Biobank
Topless et al., BMJ Open, doi:10.1136/bmjopen-2022-062945
Topless et al., Folic acid and methotrexate use and their association with COVID-19 diagnosis and mortality: a case–control.., BMJ Open, doi:10.1136/bmjopen-2022-062945
Aug 2022   Source   PDF  
  All Studies   Meta
UK Biobank retrospective showing higher cases and mortality with folic acid supplementation.
risk of death, 164.0% higher, OR 2.64, p < 0.001, adjusted per study, multivariable, model 2, RR approximated with OR.
risk of case, 51.0% higher, OR 1.51, p < 0.001, adjusted per study, multivariable, model 2, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Topless et al., 24 Aug 2022, retrospective, United Kingdom, peer-reviewed, 6 authors.
Contact: gaffo@uabmc.e.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin B9All
Folic acid and methotrexate use and their association with COVID-19 diagnosis and mortality: a case–control analysis from the UK Biobank
Ruth Topless, Ralph Green, Sarah L Morgan, Philip Robinson, Tony Merriman, Dr Angelo L Gaffo
BMJ Open, doi:10.1136/bmjopen-2022-062945
Objective To determine if methotrexate or folic acid prescription was associated with differential risk for COVID-19 diagnosis or mortality. Design Case-control analysis. Setting The population-based UK Biobank (UKBB) cohort. Participants Data from 380 380 UKBB participants with general practice prescription data for 2019-2021. Updated medical information was retrieved on 13 December 2021. Primary and secondary outcome measures The outcomes of COVID-19 diagnosis and COVID-19-related mortality were analysed by multivariable logistic regression. Exposures evaluated were prescription of folic acid and/or methotrexate. Criteria for COVID-19 diagnosis were (1) a positive SARS-CoV-2 test or (2) ICD-10 code for confirmed COVID-19 (U07.1) or probable COVID-19 (U07.2) in hospital records, or death records. By these criteria, 26 003 individuals were identified with COVID-19 of whom 820 were known to have died from COVID-19. Logistic regression statistical models were adjusted for age sex, ethnicity, Townsend deprivation index, body mass index, smoking status, presence of rheumatoid arthritis, sickle cell disease, use of anticonvulsants, statins and iron supplements. Results Compared with people prescribed neither folic acid nor methotrexate, people prescribed folic acid supplementation had increased risk of diagnosis of COVID -19 (OR 1.51 (1.42-1.61)). The prescription of methotrexate with or without folic acid was not associated with COVID-19 diagnosis (p≥0.18). People prescribed folic acid supplementation had positive association with death after a diagnosis of COVID-19 (OR 2.64 (2.15-3.24)) in a fully adjusted model. The prescription of methotrexate in combination with folic acid was not associated with an increased risk for COVID-19-related death (1.07 (0.57-1.98)). Conclusions We report an association of increased risk for COVID-19 diagnosis and COVID-19-related death in people prescribed folic acid supplementation. Our results also suggest that methotrexate might attenuate these associations.
Competing interests PR reports personal fees from Abbvie, Atom Biosciences, Eli Lilly, Gilead, Janssen, Novartis, UCB, Roche, Pfizer; meeting attendance support from BMS, Pfizer and UCB Pharma and grant funding from Janssen, Novartis, Pfizer and UCB Pharma, all outside the submitted work. ALG reports personal fees from SOBI, Selecta and honoraria from UptoDate, outside the submitted work. Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research. Patient consent for publication Not applicable. Ethics approval This study involves human participants. The UK Biobank Resource (approval number 12611) was undertaken with ethical approval from the North West Multi-Centre Research Ethics Committee of the UK. This study was done under this ethical approval; researchers using the UK Biobank do not require separate ethical approval. The study complies with the Declaration of Helsinki and written informed consent was obtained from all participants. Participants gave informed consent to participate in the study before taking part. Provenance and peer review Not commissioned; externally peer reviewed. Data availability statement Data are available in a public, open access repository. Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations..
Choi, Nguyen, Niu, Selection bias in rheumatic disease research, Nat Rev Rheumatol, doi:10.1038/nrrheum.2014.36
Davies, Jarvis, Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7, Nature, doi:10.1038/s41586-021-03426-1
Dixit, Nettem, Madan, Folate supplementation in people with sickle cell disease, Cochrane Database Syst Rev, doi:10.2139/ssrn.3297902
Girelli, Marchi, Busti, Iron metabolism in infections: focus on COVID-19, Semin Hematol, doi:10.1053/j.seminhematol.2021.07.001
Gonciarz, Renslo, Melgar-Talavera, Ángel, Emerging role of ferrous iron in bacterial growth and host-pathogen interaction: New tools for chemical (micro)biology and antibacterial therapy, Curr Opin Chem Biol, doi:10.1016/j.atherosclerosis.2021.06.911
Green, Miller, Folate deficiency beyond megaloblastic anemia: hyperhomocysteinemia and other manifestations of dysfunctional folate status, Semin Hematol
Itelman, Wasserstrum, Segev, Clinical characterization of 162 COVID-19 patients in Israel: preliminary report from a large tertiary center, Isr Med Assoc J
Linnebank, Moskau, Semmler, American College of rheumatology guideline for the treatment of rheumatoid arthritis, Arthritis Rheumatol, doi:10.1002/art.41752
Maruvada, Stover, Mason, Knowledge gaps in understanding the metabolic and clinical effects of excess folates/ folic acid: a summary, and perspectives, from an NIH workshop, Am J Clin Nutr, doi:10.1093/ajcn/nqaa259
Morgan, Baggott, Vaughn, Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 global rheumatology alliance physician-reported registry, Arthritis Rheum, doi:10.1136/annrheumdis-2020-219498
Morgan, Baggott, Vaughn, Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial, Ann Intern Med, doi:10.7326/0003-4819-121-11-199412010-00002
Schäfer, Strangfeld, Hyrich, Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Mulhearn et, Ann Rheum Dis, doi:10.1136/annrheumdis-2021-220134
Serseg, Benarous, Yousfi, Hispidin and Lepidine E: Two Natural Compounds and Folic Acid as Potential Inhibitors of 2019-novel Coronavirus Main Protease (2019-nCoVM pro ), Molecular Docking and SAR Study, Curr Comput Aided Drug Des, doi:10.2174/1573409916666200422075440
Stegmann, Dickmanns, Gerber, The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models, Virus Res, doi:10.1016/j.virusres.2021.198469
Sudlow, Gallacher, Allen, Uk Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age, Epilepsy Behav, doi:10.1016/j.yebeh.2005.05.020
Thaker, Ch'ng, Hr, Viral hijacking of cellular metabolism, BMC Biol, doi:10.1186/s12915-019-0678-9
Wald, Morris, Blakemore, Public health failure in the prevention of neural tube defects: time to abandon the tolerable upper intake level of folate, Public Health Rev, doi:10.1186/s40985-018-0079-6
Wee, COVID-19's toll on the elderly and those with diabetes mellitus -Is vitamin B12 deficiency an accomplice?, Med Hypotheses, doi:10.1016/j.mehy.2020.110374
Zhang, Guo, Kim, SARS-CoV-2 hijacks folate and onecarbon metabolism for viral replication, doi:10.1038/s41467-021-21903-z
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop